A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared With Metformin Up-titration Alone in Subjects With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2016 Status changed from not yet recruiting to recruiting.